Shilanski & Associates Inc. Decreases Stock Position in Johnson & Johnson $JNJ

Shilanski & Associates Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,263 shares of the company’s stock after selling 85 shares during the period. Shilanski & Associates Inc.’s holdings in Johnson & Johnson were worth $346,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of JNJ. Brighton Jones LLC increased its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $218,000. Jaffetilchin Investment Partners LLC increased its stake in shares of Johnson & Johnson by 1.9% during the first quarter. Jaffetilchin Investment Partners LLC now owns 36,300 shares of the company’s stock valued at $6,020,000 after buying an additional 685 shares during the period. Philip James Wealth Mangement LLC increased its stake in shares of Johnson & Johnson by 1.7% during the first quarter. Philip James Wealth Mangement LLC now owns 77,415 shares of the company’s stock valued at $12,839,000 after buying an additional 1,257 shares during the period. Finally, Achmea Investment Management B.V. increased its stake in shares of Johnson & Johnson by 15.7% during the first quarter. Achmea Investment Management B.V. now owns 248,227 shares of the company’s stock valued at $41,166,000 after buying an additional 33,641 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Raymond James Financial boosted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Finally, Morgan Stanley set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Stock Down 0.0%

NYSE:JNJ opened at $190.31 on Tuesday. The company has a market capitalization of $458.50 billion, a PE ratio of 18.37, a P/E/G ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The firm’s 50-day moving average price is $182.54 and its 200-day moving average price is $166.65.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.